We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sulforadex in Healthy Volunteers SAD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01948362
First Posted: September 23, 2013
Last Update Posted: September 23, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Evgen Pharma
  Purpose
To determine the safety and tolerability of single escalating doses of Sulforadex® in healthy male volunteers.

Condition Intervention Phase
Stage, Prostate Cancer Drug: Sulforadex Drug: Alpha cyclodextrin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex® in Healthy Male Subjects

Resource links provided by NLM:


Further study details as provided by Evgen Pharma:

Primary Outcome Measures:
  • Safety [ Time Frame: 2 days ]
    Safety assessments will include standard laboratory safety tests (haematology, biochemistry, coagulation and urinalysis), vital signs, physical examinations, 12-lead ECG, telemetry and AE monitoring.


Enrollment: 29
Study Start Date: November 2012
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sulforadex
Active compound
Drug: Sulforadex
Active compound
Other Name: Stabilised sulforaphane
Experimental: alpha Cyclodextrin
Placebo control arm
Drug: Alpha cyclodextrin
Placebo control

Detailed Description:

This study will be conducted in a randomised, double-blind, placebo-controlled design with single ascending doses of Sulforadex® administered to healthy male subjects between 18 to 45 years of age. Each healthy subject will receive verbal and written information followed by signing of the Informed Consent Form (ICF).

Subjects will be screened within 21 days prior to admission. At this visit a medical examination will be performed to assess eligibility of the healthy subject. Screening will be conducted over 1 day or may be divided into more than 1 day. The first cohort of the study will commence with one sentinel group. The subsequent groups may be dosed together without sentinel dosing. The study is expected to have 5 cohorts with a total of 29 healthy male subjects:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male subjects aged between 18 and 45 years (inclusive) at screening.
  2. Had a Body Mass Index (BMI) between 18.5 and 25.0 kg/m2 (inclusive) at screening.
  3. Subjects agreed to use acceptable methods of contraception

Exclusion Criteria:

  1. Subjects could not refrain from eating brassica vegetables or using brassica containing supplements for at least 7 days prior to the drug administration.
  2. History or clinical evidence of clinically significant disease or any condition or disease that affects drug absorption, distribution or excretion.
  3. Any history of clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission.
  4. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening and Day -1) and 24-hour 5-lead Holter ECG (at screening) which in the opinion of the Investigator interfered with the ECG analysis.
  5. Any history or current evidence of clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease.
  6. Positive screen for Hepatitis B (Hepatitis B surface Antigen, HBsAG), Hepatitis C (Hepatitis C Antibody, anti-HCV) or HIV.
  7. Confirmed positive results from urine drug screen at screening and on admission (Day

    -1) indicating drug abuse including: amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates, tricyclic antidepressants and methadone or a confirmed positive alcohol breath test at screening and on admission (Day -1).

  8. History or clinical evidence of alcoholism or drug abuse. Alcohol abuse is defined as regular weekly intake of more than 14 units if female and 21 units if male (Using alcohol tracker http://www.nhs.uk/Tools/Pages/NHSAlcoholtracker.aspx); drug abuse is defined as compulsive, repetitive and/or chronic use of drugs or other substances with or without problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms.
  9. Subject was mentally handicapped.
  10. Participation in another drug trial within 90 days prior to first drug administration.
  11. Use of any medication (including over-the-counter [OTC] medication) within 2 weeks prior to admission (Day 1) or within 10 times the elimination half-life of the respective drug or anticipated concomitant medication during the treatment periods. Limited amounts of paracetamol were allowed to treat AEs.
  12. Subjects who had donated more than 500 mL of blood within 90 days prior to drug administration.
  13. Smoking more than 10 cigarettes or equivalent amount of tobacco per day and subjects who could not stop smoking for the duration of the study whilst in the CPU.
  14. Treatment with herbal or sulforaphane containing supplements during the 7 days prior to dosing, or use of vitamins during 48 hours prior to admission (Day -1).
  15. Any circumstances or condition(s) that in the opinion of the Investigator would compromise full participation in the trial or compliance with the protocol.
  16. Subjects with legal incapacity or limited legal capacity at screening.
  17. Subjects who were vegetarians, vegans or have medical dietary restrictions.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01948362


Locations
United Kingdom
Richmond Pharmacology
London, United Kingdom, SW17 0RE
Sponsors and Collaborators
Evgen Pharma
Investigators
Principal Investigator: Jörg Täube, MD FFPM Richmond Pharmacology
  More Information

Responsible Party: Evgen Pharma
ClinicalTrials.gov Identifier: NCT01948362     History of Changes
Other Study ID Numbers: EVG001N
First Submitted: September 11, 2013
First Posted: September 23, 2013
Last Update Posted: September 23, 2013
Last Verified: September 2013


To Top